Literature DB >> 26694187

Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Alessandro Conti1, Matteo Santoni2, Luciano Burattini2, Marina Scarpelli3, Roberta Mazzucchelli3, Andrea B Galosi1, Liang Cheng4, Antonio Lopez-Beltran5, Alberto Briganti6, Francesco Montorsi6, Rodolfo Montironi7.   

Abstract

BACKGROUND: Metastases to lymph nodes (LNs) represent an unfavorable prognostic factor in patients with prostate cancer (PCa). Histological examination represents the gold standard in the evaluation of the lymphadenectomy (LND) specimens for the presence of secondary deposits. METHODS AND
RESULTS: The metastatic detection rate can vary according to the approach adopted in the microscopic analysis of the LNs, which includes frozen-section examination, total inclusion of the tissue with and without whole-mount sections, serial sectioning, and the application of immunohistochemistry. The assessment of the sentinel LN, the search for micrometastases, and the evaluation of atypical LN metastatic sites further contribute to the detection of the metastatic spread.
CONCLUSION: In this review, an update on the histopathological evaluation of LND specimens in patients with PCa is given, and focus is made on their clinical and prognostic significance.

Entities:  

Keywords:  Lymph nodes; Metastases; Prostate cancer

Mesh:

Year:  2015        PMID: 26694187     DOI: 10.1007/s00345-015-1752-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  75 in total

1.  Periprostatic lymph node metastasis in prostate cancer and its clinical significance.

Authors:  Fang-Ming Deng; Savvas E Mendrinos; Kasturi Das; Jonathan Melamed
Journal:  Histopathology       Date:  2012-02-28       Impact factor: 5.087

2.  NKX3.1 as a marker of prostatic origin in metastatic tumors.

Authors:  Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

3.  Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Authors:  Jonathan I Epstein; Lars Egevad; Peter A Humphrey; Rodolfo Montironi
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

4.  Re: Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer.

Authors:  Oleksandr N Kryvenko; Jonathan I Epstein
Journal:  Pathology       Date:  2015-06       Impact factor: 5.306

5.  Visualisation of the lymph node pathway in real time by laparoscopic radioisotope- and fluorescence-guided sentinel lymph node dissection in prostate cancer staging.

Authors:  Stephan Jeschke; Lukas Lusuardi; Andy Myatt; Stephan Hruby; Christian Pirich; Guenter Janetschek
Journal:  Urology       Date:  2012-09-15       Impact factor: 2.649

6.  Extranodal extension in lymph node-positive prostate cancer.

Authors:  L Cheng; T M Pisansky; D M Ramnani; B C Leibovich; J C Cheville; J Slezak; E J Bergstralh; H Zincke; D G Bostwick
Journal:  Mod Pathol       Date:  2000-02       Impact factor: 7.842

7.  Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer.

Authors:  T L Griebling; D Ozkutlu; W A See; M B Cohen
Journal:  Mod Pathol       Date:  1997-08       Impact factor: 7.842

8.  The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes.

Authors:  J Mikel Hubanks; Stephen A Boorjian; Igor Frank; Matthew T Gettman; R Houston Thompson; Laureano J Rangel; Eric J Bergstralh; R Jeffrey Karnes
Journal:  Urol Oncol       Date:  2013-02-06       Impact factor: 3.498

9.  Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.

Authors:  Joost L Boormans; Mark F Wildhagen; Chris H Bangma; Paul C Verhagen; Geert J van Leenders
Journal:  BJU Int       Date:  2008-08-14       Impact factor: 5.588

10.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.

Authors:  Tobias Maurer; Gregor Weirich; Margret Schottelius; Martina Weineisen; Benjamin Frisch; Asli Okur; Hubert Kübler; Mark Thalgott; Nassir Navab; Markus Schwaiger; Hans-Jürgen Wester; Jürgen E Gschwend; Matthias Eiber
Journal:  Eur Urol       Date:  2015-05-06       Impact factor: 20.096

View more
  4 in total

1.  Lymph node dissection in urological cancers: one topic, many controversies.

Authors:  Avinash Nehra; R Jeffrey Karnes; Giorgio Gandaglia; Alberto Briganti
Journal:  World J Urol       Date:  2017-03-01       Impact factor: 4.226

Review 2.  Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis.

Authors:  Claudio Luchini; Achim Fleischmann; Joost L Boormans; Matteo Fassan; Alessia Nottegar; Paola Lucato; Brendon Stubbs; Marco Solmi; Antonio Porcaro; Nicola Veronese; Matteo Brunelli; Aldo Scarpa; Liang Cheng
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

3.  Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis.

Authors:  Xueju Wang; Qiang Wen; Haishan Zhang; Bin Ji
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244

4.  Magnetic resonance imaging at ultra-high magnetic field strength: An in vivo assessment of number, size and distribution of pelvic lymph nodes.

Authors:  Ansje S Fortuin; Bart W J Philips; Marloes M G van der Leest; Mark E Ladd; Stephan Orzada; Marnix C Maas; Tom W J Scheenen
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.